{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T19:15:41Z","timestamp":1790363741291,"version":"4.1.0"},"reference-count":48,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Drug repurposing or drug repositioning is the process of identifying new therapeutic uses for approved or investigational drugs beyond the original treatment indication. The discovery of new drugs for cancer therapy needs this cost-effective and time-saving alternative strategy to traditional drug development for a rapid clinical translation in Phase II\/III studies, especially for unmet medical needs and rare diseases. Neuroendocrine tumors (NETs) are a heterogeneous group of rare neoplasms arising from cells of the neuroendocrine system that, though often indolent, can be aggressive and metastatic. In this context, drug repurposing has emerged as a promising strategy to improve treatment options due to the limited number of effective treatments and the heterogeneity of the disease. Indeed, a large number of non-oncology drugs have the potential to address more than one target that could be therapeutic for cancer patients. Although many repurposed drugs are used off-label, efficacy for the new use must be demonstrated in clinical trials. Within regulatory frameworks, both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have procedures to reduce the need for extensive new studies and to expedite the review of drugs for serious conditions when preliminary evidence indicates substantial clinical improvement over available therapy. In spite of several advantages, including reduced development time, lower costs, known safety profiles, and faster regulatory approval, difficulty in obtaining new patents for old drugs with limited protection for intellectual property may reduce commercial returns and disincentivize investments. This review aims to provide comprehensive information on some marketed drugs currently under investigation to be repurposed or used in clinical practice for NETs and to discuss the major clinical challenges. Although drug repurposing is a useful strategy for early access to medicines, the monitoring of the clinical benefit of oncologic drugs during the post-marketing authorization is crucial to support the safety and effectiveness of treatments.<\/jats:p>","DOI":"10.3390\/cancers17152488","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T14:05:47Z","timestamp":1753711547000},"page":"2488","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Drug Repurposing of New Treatments for Neuroendocrine Tumors"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1149-3835","authenticated-orcid":false,"given":"Stefania","family":"Bellino","sequence":"first","affiliation":[{"name":"National Center for Drug Research and Evaluation, Istituto Superiore di Sanit\u00e0, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Lucente","sequence":"additional","affiliation":[{"name":"National Center for Drug Research and Evaluation, Istituto Superiore di Sanit\u00e0, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5020-8657","authenticated-orcid":false,"given":"Anna","family":"La Salvia","sequence":"additional","affiliation":[{"name":"National Center for Drug Research and Evaluation, Istituto Superiore di Sanit\u00e0, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41392-024-01808-1","article-title":"Drug repurposing for cancer therapy","volume":"9","author":"Xia","year":"2024","journal-title":"Signal Transduct. Target Ther."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the Incidence, Prevalence, and Survival Outcomes in Patients with Neuroendocrine Tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s12022-022-09708-2","article-title":"Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms","volume":"33","author":"Rindi","year":"2022","journal-title":"Endocr. Pathol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"158","DOI":"10.23736\/S2724-6507.23.04140-4","article-title":"Recent advances and future challenges in the diagnosis of neuroendocrine neoplasms","volume":"49","author":"Modica","year":"2024","journal-title":"Minerva Endocrinol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1002\/cncr.35463","article-title":"Update in the management of gastroenteropancreatic neuroendocrine tumors","volume":"130","author":"Sedlack","year":"2024","journal-title":"Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"101794","DOI":"10.1016\/j.beem.2023.101794","article-title":"Precision medicine in gastroenteropancreatic neuroendocrine neoplasms: Where are we in 2023?","volume":"37","author":"Fazio","year":"2023","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"R173","DOI":"10.1530\/ERC-15-0413","article-title":"Predictive factors of response to mTOR inhibitors in neuroendocrine tumours","volume":"23","author":"Zatelli","year":"2016","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_8","unstructured":"FDA (2025, June 23). Guidance for Industry: Applications Covered by Section 505(b)(2), Available online: https:\/\/www.fda.gov\/media\/72419\/download."},{"key":"ref_9","unstructured":"FDA (2025, June 23). Breakthrough Therapy, Available online: https:\/\/www.fda.gov\/patients\/fast-track-breakthrough-therapy-accelerated-approval-priority-review\/breakthrough-therapy."},{"key":"ref_10","unstructured":"EMA (2025, June 23). (EMA) Has the Type II Variation. Available online: https:\/\/www.ema.europa.eu\/en\/glossary-terms\/type-ii-variation."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1134\/S1068162023020139","article-title":"Drug Repurposing: An Effective Tool in Modern Drug Discovery","volume":"49","author":"Kulkarni","year":"2023","journal-title":"Russ. J. Bioorg. Chem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/bph.13798","article-title":"Drug repurposing from the perspective of pharmaceutical companies","volume":"175","author":"Cha","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"March-Vila, E., Pinzi, L., Sturm, N., Tinivella, A., Engkvist, O., Chen, H., and Rastelli, G. (2017). On the Integration of In Silico Drug Design Methods for Drug Repurposing. Front. Pharmacol., 8.","DOI":"10.3389\/fphar.2017.00298"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"59","DOI":"10.12793\/tcp.2019.27.2.59","article-title":"A review of computational drug repurposing","volume":"27","author":"Park","year":"2019","journal-title":"Transl. Clin. Pharmacol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1016\/j.drudis.2019.06.014","article-title":"Drug repurposing: A promising tool to accelerate the drug discovery process","volume":"24","author":"Parvathaneni","year":"2019","journal-title":"Drug Discov. Today"},{"key":"ref_16","unstructured":"EMA Afinitor (Everolimus) (2025, June 23). Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/afinitor-epar-product-information_en.pdf."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1177\/1756283X13496970","article-title":"Everolimus in the treatment of patients with advanced pancreatic neuroendocrine tumors: Latest findings and interpretations","volume":"6","author":"Liu","year":"2013","journal-title":"Ther. Adv. Gastroenterol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","article-title":"Everolimus for the treatment of advanced, nonfunctional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): A randomised, placebo-controlled, phase 3 study","volume":"387","author":"Yao","year":"2016","journal-title":"Lancet"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"S754","DOI":"10.1016\/j.annonc.2024.08.1209","article-title":"Search for biomarkers to personalize treatment with streptozotocin plus 5-fluorouracil or everolimus in patients with advanced pancreatic neuroendocrine tumors: The randomized phase III SEQTOR trial (GETNE-1206)","volume":"35","author":"Soler","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1080\/14656566.2018.1476492","article-title":"Everolimus in treatment of neuroendocrine tumors: Efficacy, side-effects, resistance and factors affecting its place in the treatment sequence","volume":"19","author":"Lee","year":"2018","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Medici, B., Caffari, E., Maculan, Y., Benatti, S., Piacentini, F., Dominici, M., and Gelsomino, F. (2025). Everolimus in the Treatment of Neuroendocrine Tumors: Lights and Shadows. Biomedicines, 13.","DOI":"10.3390\/biomedicines13020455"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"501","DOI":"10.33549\/physiolres.934618","article-title":"The role of AMPK\/mTOR signaling pathway in anticancer activity of metformin","volume":"70","author":"Chomanicova","year":"2021","journal-title":"Physiol. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"759","DOI":"10.3748\/wjg.v30.i7.759","article-title":"Metformin and pancreatic neuroendocrine tumors: A systematic review and meta-analysis","volume":"30","author":"Coppola","year":"2024","journal-title":"World J. Gastroenterol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1053\/j.gastro.2018.04.010","article-title":"Metformin Use Is Associated with Longer Progression-Free Survival of Patients with Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and\/or Somatostatin Analogues","volume":"155","author":"Pusceddu","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Duarte, J.A., de Barros, A.L.B., and Leite, E.A. (2021). The potential use of simvastatin for cancer treatment: A review. Biomed. Pharmacother., 141.","DOI":"10.1016\/j.biopha.2021.111858"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1007\/s12020-024-03767-7","article-title":"Dyslipidemia, lipid-lowering agents and neuroendocrine neoplasms: New horizons","volume":"85","author":"Modica","year":"2024","journal-title":"Endocrine"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e13485","DOI":"10.1111\/jne.13485","article-title":"Impact of dyslipidemia and lipid-lowering therapy with statins in patients with neuroendocrine tumors","volume":"37","author":"Faggiano","year":"2025","journal-title":"J. Neuroendocrinol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1158\/2159-8290.CD-13-0183","article-title":"A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors","volume":"3","author":"Jahchan","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1158\/2159-8290.CD-13-0790","article-title":"Teaching an old dog new tricks: Drug repositioning in small cell lung cancer","volume":"3","author":"Wang","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_31","first-page":"100174","article-title":"A phase IIa study repositioning desipramine in small cell lung and other high-grade neuroendocrine tumors","volume":"23","author":"Riess","year":"2020","journal-title":"Cancer Treat Res. Commun."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1093\/annonc\/mdh300","article-title":"Thalidomide in cancer medicine","volume":"15","author":"Bamias","year":"2004","journal-title":"Ann. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","article-title":"Thalidomide is an inhibitor of angiogenesis","volume":"91","author":"Loughran","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_34","unstructured":"EMA (2025, June 23). Thalidomide. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/thalidomide-bms-epar-product-information_en.pdf."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1093\/annonc\/mdm009","article-title":"New drug development in digestive neuroendocrine tumors","volume":"18","author":"Salazar","year":"2007","journal-title":"Ann. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1159\/000430816","article-title":"Temozolomide in Advanced Neuroendocrine Neoplasms: Pharmacological and Clinical Aspects","volume":"101","author":"Koumarianou","year":"2015","journal-title":"Neuroendocrinology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"101667","DOI":"10.1016\/j.eclinm.2022.101667","article-title":"S-1\/temozolomide versus S-1\/temozolomide plus thalidomide in advanced pancreatic and non-pancreatic neuroendocrine tumours (STEM): A randomised, open-label, multicentre phase 2 trial","volume":"54","author":"Chi","year":"2022","journal-title":"EClinicalMedicine"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1159\/000500812","article-title":"A New Generation Somatostatin-Dopamine Analogue Exerts Potent Antitumoral Actions on Pituitary Neuroendocrine Tumor Cells","volume":"110","author":"Solivera","year":"2020","journal-title":"Neuroendocrinology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"112159","DOI":"10.1016\/j.intimp.2024.112159","article-title":"Disulfiram mediated anti-tumour effect in pituitary neuroendocrine tumours by inducing cuproptosis","volume":"134","author":"Huang","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/s41392-022-01229-y","article-title":"Copper homeostasis and cuproptosis in health and disease","volume":"7","author":"Liyun","year":"2022","journal-title":"Signal Transduct. Target Ther."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Bian, C., Zheng, Z., Su, J., Chang, S., Yu, H., Bao, J., Xin, Y., and Jiang, X. (2023). Copper homeostasis and cuproptosis in tumor pathogenesis and therapeutic strategies. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1271613"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12943-023-01732-y","article-title":"Cuproptosis: Mechanisms and links with cancers","volume":"22","author":"Xie","year":"2023","journal-title":"Mol. Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"781","DOI":"10.3332\/ecancer.2017.781","article-title":"Repurposing Drugs in Oncology (ReDO)-chloroquine and hydroxychloroquine as anti-cancer agents","volume":"11","author":"Verbaanderd","year":"2017","journal-title":"ecancermedicalscience"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1530\/ERC-20-0028","article-title":"Chloroquine induces apoptosis in pancreatic neuroendocrine neoplasms via endoplasmic reticulum stress","volume":"27","author":"Nakano","year":"2020","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Li, J., Shi, X., Tang, T., Zhou, M., and Ye, F. (2024). Research progress on nonsteroidal anti-inflammatory drugs in the treatment of pituitary neuroendocrine tumors. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1407387"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Sulsenti, R., Frossi, B., Bongiovanni, L., Cancila, V., Ostano, P., Fischetti, I., Enriquez, C., Guana, F., Chiorino, G., and Tripodo, C. (2021). Repurposing of the Antiepileptic Drug Levetiracetam to Restrain Neuroendocrine Prostate Cancer and Inhibit Mast Cell Support to Adenocarcinoma. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.622001"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Elhasasna, H., Khan, R., Bhanumathy, K.K., Vizeacoumar, F.S., Walke, P., Bautista, M., Dahiya, D.K., Maranda, V., Patel, H., and Balagopal, A. (2022). A Drug Repurposing Screen Identifies Fludarabine Phosphate as a Potential Therapeutic Agent for N-MYC Overexpressing Neuroendocrine Prostate Cancers. Cells, 11.","DOI":"10.3390\/cells11142246"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1007\/s13402-023-00822-9","article-title":"Repurposing ketotifen as a therapeutic strategy for neuroendocrine prostate cancer by targeting the IL-6\/STAT3 pathway","volume":"46","author":"Ji","year":"2023","journal-title":"Cell. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/15\/2488\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:17:18Z","timestamp":1760033838000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/15\/2488"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":48,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["cancers17152488"],"URL":"https:\/\/doi.org\/10.3390\/cancers17152488","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,28]]}}}